Summary of COVID-19 fenretinide studies

1. Houle et al., RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease

125 patient fenretinide late treatment RCT: 44% higher mortality (p=0.34).
RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b).
May 2024, NCT04417257, https://clinicaltrials.gov/study/NCT04417257, https://c19p.org/houle